Hutchison China MediTech Limited HCM · Stock Open Hutchison China MediTech Limited in new tab
Hutchison China MediTech Limited Analysis (HCM)
Is Hutchison China MediTech Limited a good investment? Hutchison China MediTech Limited (HCM) is currently trading at 11.52 USD. Market analysts have a consensus price target of 21.77 USD. This suggests a potential upside from current levels.
In terms of valuation, the stock trades at a P/E ratio of 111.30. This high multiple suggests investors have priced in significant future growth expectations.
Earnings Schedule: Hutchison China MediTech Limited is expected to release its next earnings report on March 4, 2027. The market consensus estimate for Forward EPS is 0.23.
Investor FAQ
Does Hutchison China MediTech Limited pay a dividend?
No, it does not currently pay a dividend.
What asset class is Hutchison China MediTech Limited?
Hutchison China MediTech Limited is classified as a Stock. You can compare it against 2 other assets in the "Related Symbols" list on this page.
When is the next earnings date?
The next earnings date is projected to be March 4, 2027. The company currently has a trailing EPS of 0.10.
Company Profile
HUTCHMED (China) Limited, together with its subsidiaries, discovers, develops, and commercializes targeted therapeutics and immunotherapies to treat cancer and immunological diseases in Hong Kong, the United States, and internationally. It provides Fruquintinib, a selective and potent oral inhibitor of vascular endothelial growth factor receptors for treatment of colorectal cancer (CRC), breast cancer, gastric cancer (GC), microsatellite stable-CRC endometrial cancer (EMC), non-small cell lung cancer (NSCLC), renal cell carcinoma (RCC), endometrial cancer (EMC); and Savolitinib, a potent and selective inhibitor of mesenchymal-epithelial transition receptor to treat NSCLC, papillary RCC, and GC. It also develops Surufatinib to treat pancreatic neuroendocrine tumor (NET), non pancreatic NET, and pancreatic ductal adenocarcinoma; Sovleplenib, to treat immune thrombocytopenic purpura and warm autoimmune hemolytic anemia; and Tazemetostat, a treatment for epithelioid sarcoma and follicular lymphoma; Fanregratinib that treats intrahepatic cholangiocarcinoma; and Ranosidenib, a novel dual-inhibitor of dehydrogenase-1 and isocitrate dehydrogenase-2 enzymes to treat acute myeloid leukemia (AML). In addition, the company is developing HMPL-760, which is in phase I and II clinical trial to treat relapsed and/or refractory diffuse large B cell lymphoma, chronic lymphocytic leukemia, small lymphocytic lymphoma, and other B-NHL; HMPL-506 to treat Mixed-lineage leukemia-rearrange/rearrangement and nucleophosmin 1-mutantAML. It has collaboration agreements with AstraZeneca AB (publ), Lilly (Shanghai) Management Company Limited, Takeda, Inmagene Biopharmaceuticals Co. Ltd., Innovent Biologics Co., Inc., and Epizyme, Inc., and Epizyme, Inc. The company was formerly known as Hutchison China MediTech Limited and changed its name to HUTCHMED (China) Limited in May 2021. HUTCHMED (China) Limited was incorporated in 2000 and is headquartered in Hong Kong, Hong Kong.
| Split Date | Split Ratio to 1 |
|---|---|
| May 30, 2019 | 10.000000 |
Community Discussion